Evidence map›Paper›PMID 23646159›Full record

ArticlePloS one2013

Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.

Edith T Zemanick, J Kirk Harris, Brandie D Wagner, Charles E Robertson, Scott D Sagel, Mark J Stevens, Frank J Accurso, Theresa A Laguna

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04765033 (Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease), which is not on this map. Cited by 102 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 2 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04765033 phase4completednot on this mapstarted 2021, after this paper: background citation

Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease

TypeinterventionalSponsorUniversity of MalayaRan2021 to 2023Enrolled46ConditionsBronchiectasisArmsNebulized 5% Hypertonic saline
3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 2 syntheses or guidelines pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Journal of bacteriology · 2026
    Review
  6. ERJ open research · 2025
    Article
  7. Genomic diversity inMicrobial genomics · 2025
    Article
  8. Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Upper airway microbiota development in infants with cystic fibrosis diagnosed by newborn screen.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023
    Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. The European respiratory journal · 2022
    Article
  19. Article
  20. Journal of medical microbiology · 2022
    Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Edith T ZemanickDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, United States of America. edith.zemanick@childrenscolorado.org
J Kirk Harris
Brandie D Wagner
Charles E Robertson
Scott D Sagel
Mark J Stevens
Frank J Accurso
Theresa A Laguna
University of Colorado Denver · USUniversity of Colorado Boulder · USUniversity of Minnesota Children's Hospital · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
Bedside to Bench and Back Again: Training Pediatricians in Translational ResearchK12HD068322 · NICHD · UNIVERSITY OF MINNESOTA · PI NEGLIA, JOSEPH P · 2011 to 2015
$1.9M
NCRR NIH HHS 1UL 1RR025780-01NCRR NIH HHS UL1 RR025780NICHD NIH HHS K12 HD068322
6 · The paper itself

Abstract

backgroundPulmonary exacerbations (PEx), frequently associated with airway infection and inflammation, are the leading cause of morbidity in cystic fibrosis (CF). Molecular microbiologic approaches detect complex microbiota from CF airway samples taken during PEx. The relationship between airway microbiota, inflammation, and lung function during CF PEx is not well understood.

objectiveTo determine the relationships between airway microbiota, inflammation, and lung function in CF subjects treated for PEx.

methodsExpectorated sputum and blood were collected and lung function testing performed in CF subjects during early (0-3d.) and late treatment (>7d.) for PEx. Sputum was analyzed by culture, pyrosequencing of 16S rRNA amplicons, and quantitative PCR for total and specific bacteria. Sputum IL-8 and neutrophil elastase (NE); and circulating C-reactive protein (CRP) were measured.

resultsThirty-seven sputum samples were collected from 21 CF subjects. At early treatment, lower diversity was associated with high relative abundance (RA) of Pseudomonas (r = -0.67, p<0.001), decreased FEV(1%) predicted (r = 0.49, p = 0.03) and increased CRP (r = -0.58, p = 0.01). In contrast to Pseudomonas, obligate and facultative anaerobic genera were associated with less inflammation and higher FEV₁. With treatment, Pseudomonas RA and P. aeruginosa by qPCR decreased while anaerobic genera showed marked variability in response. Change in RA of Prevotella was associated with more variability in FEV₁ response to treatment than Pseudomonas or Staphylococcus.

conclusionsAnaerobes identified from sputum by sequencing are associated with less inflammation and higher lung function compared to Pseudomonas at early exacerbation. CF PEx treatment results in variable changes of anaerobic genera suggesting the need for larger studies particularly of patients without traditional CF pathogens.

Indexed as

MetagenomeAdolescentAdultAnti-Bacterial AgentsBacteriaChildCross-Sectional StudiesCystic FibrosisFemaleHumansInflammationMaleRespiratory Function TestsRespiratory SystemSputumYoung AdultAnti-Bacterial Agents

Identifiers

PMID23646159
PMCPMC3639911
OpenAlexW2072180249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.